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Abstract
Background: Elevated fractional exhaled nitric oxide (FENO) associates positively
with symptomatic atopy among asthmatics and in the general population. It is,
however, unclear whether sensitization to common allergens per se –a sv e r i ﬁ e d
with positive skin prick tests – affects FENO in healthy individuals.
Objective: Theaimof thisstudywastoexaminetheassociationbetweenFENOand
sensitization to common allergens in healthy nonsmoking adults with no signs or
symptoms of airway disorders.
Methods: FENO measurements (ﬂow rate: 50 mL/s), skin prick tests to common
inhalant allergens, structured interviews, spirometry, bronchodilatation tests and
bronchial histamine challenges were performed on a randomly selected population
of 248 subjects. Seventy-three of them (29%) were nonsmoking asymptomatic
adults with no history of asthma, persistent or recurrent upper or lower airway
symptoms and no signs of airway disorders in the tests listed above.
Results: FENO concentrations were similar in skin prick test positive (n = 32) and
negative(n = 41)healthysubjects,withmedianvaluesof 13.2and15.5 ppb,respec-
tively (P = 0.304). No correlation appeared between FENO and the number of
positive reactions (r =- 0.138; P = 0.244), or the total sum of wheal diameters
(r =- 0.135; P = 0.254). The nonparametric one-tailed 95% upper limits of FENO
among skin prick positive and negative healthy nonsmoking subjects were 29 and
31 ppb, respectively.
Conclusions: Atopic constitution deﬁned as positive skin prick test results does not
increase FENO in healthy nonsmoking adults with no signs or symptoms of airway
disorders.ThissuggeststhatsamereferencerangesforFENOcanbeappliedtoboth
skin prick test positive and negative subjects.
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Fractional exhaled nitric oxide (FENO) is a useful,
noninvasive marker for assessment of eosinophilic
airway inﬂammation (1). It is elevated in patients with
asthma-like symptoms (2) and in asthma (2, 3), espe-
cially in atopic asthma (4). FENO rapidly decreases
with anti-inﬂammatory therapy (1), and increases
again with deterioration of asthma control (1). FENO
measurement may serve as a useful tool in the diagno-
sis of asthma and in the early detection of eosinophilic
airway inﬂammation (1, 5), as well as in guiding anti-
inﬂammatory treatment of asthma (6).
Many studies have addressed the effect of clinical
atopic conditions on FENO. While FENO levels have
been higher in atopic than in nonatopic asthma, it is
unclear whether healthy atopic subjects without symp-
toms or signs of airway disorders also have higher
FENO levels than nonatopic subjects (7–13). Studies
based on general population samples have generally
found FENO to be higher in atopic than in nonatopic
subjects (8, 11, 13). Variable results may be explained
by differences in study populations, deﬁnition of
atopy and in the expiratory ﬂow rates used in FENO
measurements. Two recent landmark studies (12, 13)
deﬁne reference ranges of FENO for adults, but leave
open the question of whether reference populations
couldincludehealthysubjectsregardlessof theiratopic
constitution.
The aim of the present study was to examine the
association of FENO and skin prick test results in
healthy nonsmoking adults with no symptoms or signs
of airway disorders assessed by structured interviews,
spirometry and bronchial challenge tests.
Materials and methods
Study population and design
The present study population originated from the
FinEsS study, which is a large epidemiological investi-
gation on obstructive lung diseases, respiratory symp-
toms and type I allergies carried out in Finland (Fin),
Estonia(Es)andSweden(S).Aspartof FinEsS,apostal
questionnaire was sent in 1996 to 8000 20- to 69-year-
old inhabitants of Helsinki. The study sample was
obtained from the Population Register Center, ran-
domized by 10-year age cohorts and by gender. The
results from that study have been reported previously
(14). Of the 6062 postal survey responders, 1200 sub-
jects were later randomly selected and invited for
clinical studies (spirometry, bronchodilatation tests,
skin prick tests and structured interviews). Half (600)
of them were at the same time further randomized
to FENO measurements and histamine challenges.
Of the 600 invited, 310 (51.7%) participated in the
study.
The 310 subjects, aged 26–65 years, underwent on
the ﬁrst study day a structured interview, ﬂow-volume
spirometry and a bronchodilatation test as explained
later. Skin prick tests were performed on the same day
on those younger than 61 years of age.FENO measure-
ments and histamine challenges, in that order, were
performed on the second study day, which was 1–14
days after the ﬁrst session. The measurements were
carried out throughout the period from May 2001 to
March 2003.
A technically acceptable FENO measurement was
obtained from 295 subjects, with skin prick test data
available from 248 of them (84%). From this popula-
tion,subjects were included in the present comparative
analysis, provided they had: (i) no signiﬁcant smoking
history (nonsmokers or ex-smokers with a history of
<5 pack-years and smoking cessation >5y e a r sp r e v i -
ously);(ii) no signs of airway obstruction [forced expi-
ratory volume in 1 s (FEV1)/forced vital capacity
(FVC)  88% of predicted (15), and bronchodilator
response < 12% increase in FEV1]; (iii) no signiﬁcant
bronchial hyperresponsiveness (PD15FEV1 > 0.4 mg
histamine (16)); (iv) no previously diagnosed asthma,
chronic bronchitis or chronic obstructive pulmonary
disease, chronic or recurrent symptoms from the
upper or lower respiratory tracts (cough, sputum pro-
duction, wheezing, shortness of breath, nasal symp-
toms related to speciﬁc allergens); or (v) no symptoms
of cardiovascular, gastrointestinal or neurological
diseases. Obesity as such was not regarded as an exclu-
sion criterion.Furthermore,the subjects had to be free
from acute respiratory infections for the 3 weeks prior
tothestudy.Afterthatexclusionprocess,theremaining
73, out of the 248 subjects, formed the study popula-
tion of healthy asymptomatic nonsmoking adults
(Fig. 1). The characteristics of the original random
population of 248 subjects and of the further analyzed
73 subjects are given in Table 1. No differences
appeared between skin prick test positive and negative
healthy subjects in relation to anthropometric or
spirometric variables.
FENO measurement
FENO was measured with a chemiluminescence ana-
lyzer(Sievers270B;Boulder,CO,USA).Two-pointcali-
bration of the analyzer was performed daily before
FENO measurements were taken. The expiratory
airﬂow and exhaled volume were measured with a
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Jaeger GmbH, Wurzburg, Germany) simultaneously
with FENO in real time.The exhalation procedure ful-
ﬁlled the criteria deﬁned in the European Respiratory
Society/American Thoracic Society (ATS) guidelines
on exhaled FENO measurements (17).Before the mea-
surement, subjects rinsed their mouths with sodium
bicarbonate solution (Hartwall Novelle®; Oy Hartwall
AB, Helsinki, Finland) to eliminate any nitric oxide
eventually produced in the mouth. After inhalation of
NO-freegas(100%oxygen),subjectsexhaledfromtotal
lung capacity with a ﬂow rate of 50 mL/s against a ﬂow
resistor (Hans Rudolph, Shawnee, KS, USA; model
#7100R,200 cmH2O/L/s,ﬂowrange:0–0.1 L/s)toclose
the soft palate,thus avoiding any nasal NO contamina-
tion.No nose clips were used.The subjects maintained
the required ﬂow rate with the aid of a visual feedback
from the computer screen. The mean ﬂow rate for
acceptable measurement was between 0.045 and
0.055 L/s, and the duration of exhalation was at least
10 s. The mean value taken from a 3-s period from the
end-exhaled NO plateau was recorded for analysis. At
FENO 13.9 (2.1–95.6) Original random population, 248 subjects
73 Healthy asymptomatic subjects
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Bronchodilator response of FEV1 ≥ 12%
PD15FEV1 ≤ 0.4 mg histamine
FEV1/FVC < 88% of predicted
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Other respiratory symptoms
Other significant diseases (epilepsia and
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FENO 20.9 (13.9–42.6)
FENO 15.3 (13.2–45.3)
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FENO 16.0 (9.0–95.6)
FENO 17.2 (13.0, 21.5)
FENO 23.0 (11.6–43.6)
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FENO 15.5 (2.1–95.6)
FENO 15.5 (2.1–49.8)
FENO 15.5 (2.1–49.8) Figure 1. Exclusion process to select
healthy asymptomatic nonsmoking
subjects, with fractional exhaled nitric
oxide (FENO) median and range shown
for each subgroup.
Table 1. Characteristics of the studied populations
All subjects
(n = 248)
Healthy subjects
(n = 73)
Skin prick test
positive (n = 32)
Skin prick test
negative (n = 41)
Gender Male/Female 106/142 27/46 11/21 16/25
Atopy Atopics/Nonatopics 116/132 32/41 32/0 0/41
Smoking history Non-/Ex-/Current
smokers
121/38/89 73/0/0 32/0/0 41/0/0
Age (years) Mean (range) 45 (26–61) 44 (27–61) 43 (27–61) 45 (28–61)
Height (cm) Mean (range) 170.5 (146–198) 170.8 (155–189) 170.3 (156–189) 171.3 (155–188)
Weight (kg) Mean (range) 74.5 (45–139) 71.8 (45–111) 70.7 (45–96) 72.6 (56–111)
Body mass index Mean (range) 25.5 (17.1–53.3) 24.5 (18.5–38.9) 24.3 (18.5–34.0) 24.7 (19.3–38.9)
FVC (L) Mean (range) 4.4 (2.2–7.5) 4.4 (2.7–6.3) 4.4 (2.7–6.3) 4.4 (3.0–6.2)
FVC, % of predicted* Mean (range) 98.1 (67–145) 99.4 (72–145) 99.4 (72–125) 99.3 (76–145)
FEV1 (L) Mean (range) 3.4 (1.0–5.6) 3.5 (2.4–5.4) 3.5 (2.4–5.0) 3.5 (2.4–5.4)
FEV1, % of predicted* Mean (range) 93.0 (41–129) 97.3 (72–129) 96.9 (75–127) 97.6 (72–129)
FEV1/FVC, % of
predicted*
Mean (range) 94.9 (55–115) 98.2 (88–115) 97.7 (88–109) 98.5 (90–115)
*Finnish reference values (15).
FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s.
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formed,andtheirmeanvaluewasrecordedforanalysis.
Theacceptablecoefﬁcientof variationof thesuccessive
FENO determinations was <0.15 (mean 0.05).
Skin prick testing
The skin prick tests were performed with 15 common
aeroallergens (cat, dog, cow, horse, birch, timothy,
mugwort, the house dust mites Dermatophagoides
pteronyssinus and Dermatophagoides farinae, the
storage mites Acarus siro and Lepidoglyphus destructor,
the outdoor molds Cladosporium and Alternaria,cock-
roach and latex) with histamine dihydrochloride
(10 mg/mL)asthepositive,andthesolvent(glycerol)as
thenegativecontrol.AllextractswereprovidedbyALK,
Hørsholm, Denmark,except latex,which was provided
by Alyostal ST-IR, Paris, France. The tests were carried
out by three experienced study nurses on the volar side
of the forearm. The reactions were inspected after
15 min,andthewhealsizewasmeasuredinmillimeters
in two perpendicular directions including the longest
diameter with their mean recorded as the response. A
response of 3 mm in the presence of expected results
to the control solutions was regarded as positive (18).
Subjects with at least one positive reaction were re-
gardedasskinpricktestpositive.Becauseof decreasing
reactivity of the skin with increasing age, subjects over
60 years of age did not undergo skin prick testing (19).
Spirometry
The FVC and FEV1 were measured according to ATS
recommendations (20), using a ﬂow-volume spirom-
eter (SensorMedixVmax 20C;Yorba Linda, CA, USA).
For bronchodilatation tests, 0.4 mg of inhaled salbuta-
mol aerosol (Ventoline®; GlaxoSmithKline, Brentford,
UK) was administered via a spacer (Volumatic®;
GlaxoSmithKline).FVC and FEV1 measurements were
repeated 15 min after the administration of salbuta-
mol.The results are expressed as absolute values and as
a percentage of the predicted value with Finnish refer-
ence values used (15).
Histamine challenge
The histamine challenge for assessment of bronchial
responsiveness was performed by a dosimetric method
with controlled tidal breathing (16) after FENO mea-
surement. A provocative dose of histamine inducing
a 15% decrease of FEV1 (PD15FEV1) was calculated
from the logarithmically transformed histamine doses
by use of linear interpolation.
Structured interview
The structured interview was conducted by one of the
ﬁve physicians involved in this part of the study, using
a questionnaire developed for the FinEsS studies. The
origins of the questionnaire have been reported
previously (21). The questionnaire included detailed
questions on recent or past respiratory symptoms,
diagnosed asthma or other chronic respiratory dis-
eases,history of cardiovascular diseases or other major
diseases, medication used and smoking history.
Statistical analysis
Statistical analyses were performed using SPSS version
11.0 for Windows (SPSS, Chicago, IL, USA). As FENO
was not normally distributed, the results are expressed
as median values and 25%–75% quartile ranges.Com-
parisons of median FENO values between the groups
were analyzed with the Mann–Whitney U-test. Com-
parisons of anthropometric and spirometric variables
between atopic and nonatopic healthy subjects were
performed using an independent sample t-test.Mutual
correlations between FENO and the number of posi-
tive skin prick tests, between FENO and the total sum
of wheal diameters as well as between FENO and age,
weightandheightwereanalyzedwithSpearman’srank
correlation coefﬁcients. All tests were two-sided, and a
P value of <0.05 was considered signiﬁcant. As FENO
was not normally distributed and normal distribution
was not achieved by log transformation, a nonpara-
metric ranking system was used for assessing the one-
tailed 95% upper limit in the groups.
Results
Results from structured interviews, FENO measure-
ments, skin prick tests, spirometry and bronchodilata-
tion tests were available from all 73 subjects fulﬁlling
the inclusion criteria of healthy asymptomatic non-
smokers, as well as from the 175 excluded subjects.
Histamine challenge results were available from 71
included subjects (two subjects refused) and from 168
excluded subjects. Three subjects had mild restrictive
ventilation impairment according to FVC and FEV1
values (scoliosis,obesity and individual body structure
[body mass index (BMI) 18]. The impact of the exclu-
sion process on median FENO values and FENO
ranges is shown in Fig. 1.
Median FENO in the 73 healthy asymptomatic non-
smoking subjects was 15.0 ppb. Median FENO was
similar in skin prick positive (n = 32) and skin prick
negative (n = 41) subjects, 13.2 and 15.5 ppb,
Asymptomatic atopy and exhaled nitric oxide Rouhos et al.
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peared between FENO and the degree of atopy deﬁned
as the number of positive reactions or as the total sum
of whealdiameters(calculatedbyaddingthediameters
of each positive reaction (3 mm) (Fig. 3). In con-
trast, among those subjects (n = 175) who were
excluded because of history, symptoms or signs of res-
piratory disease or smoking, a signiﬁcant correlation
was observed between FENO and the number of posi-
tive reactions (r = 0.160; P = 0.034) or the total sum of
wheal diameters (r = 0.178; P = 0.019), as well as in
the subpopulation of nonsmoking excluded subjects
(n = 48) (r = 0.345; P = 0.016) and (r = 0.343; P =
0.017), respectively. Mean wheal size and the total sum
of wheal diameters were signiﬁcantly higher in
excluded subjects compared with healthy subjects (4.9
and 3.8 mm,respectively (P = 0.005),and 14.1 and 8.8,
respectively (P = 0.047). The number of positive reac-
tions was similar in these groups (2.2 and 2.8, respec-
tively; P = 0.25). Of the healthy skin prick positive
subjects, 44% were sensitized to only perennial aller-
gens, 31% to only seasonal allergens and 25% to both
FENO median
15.5 ppb FENO median
13.2 ppb
41
0
10
20
30
40
50
60
P = 0.304
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Figure 2. Fractional exhaled nitric oxide (FENO) in healthy
asymptomatic skin prick positive and negative subjects. Data
are expressed as medians with interquartile range (box) and
range (whiskers) excluding an outlier (circle).
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Figure 3. Correlation between fractional exhaled nitric oxide (FENO) and the number of positive skin prick tests (A) and between
FENO and the total prick wheal sum (calculated by adding the diameters of each positive reaction) (B) in healthy nonsmoking adults
with no signs or symptoms of airway disease (n = 73).
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excluded skin prick positive subjects, the percentages
were 18%, 39% and 43%, respectively.
No signiﬁcant correlation appeared between FENO
and age (r = 0.025; P = 0.833), FENO and weight
(r = 0.222; P = 0.059) or FENO and BMI (r = 0.152;
P = 0.198),butacorrelationdidappearbetweenFENO
and height (r = 0.267; P = 0.022). The one-tailed non-
parametric 95% upper limit for FENO in the whole
group of healthy asymptomatic nonsmoking subjects
was 30 ppb,among the skin prick positive healthy sub-
jects it was 31 ppb and among skin prick test negative
healthy subjects it was 29 ppb.
Discussion
We observed similar levels of FENO in skin prick posi-
tive and negative healthy asymptomatic nonsmoking
adults with no signs of airway disorders, indicating
that atopic sensitization per se does not elevate FENO.
Horváth and Barnes found higher levels of FENO in
atopic than in nonatopic healthy asymptomatic sub-
jects (22). Their study population, however, included
only 15 atopic subjects, most of whom had mild to
moderate bronchial hyperresponsiveness on metha-
cholinechallenge.Also,Franklinet al.(8)foundhigher
FENO levels in atopic than in nonatopic subjects in a
heterogeneous study population of 115 subjects. Even
though all subjects were asymptomatic at the time of
the study, 26% had physician-diagnosed asthma, 17%
reported wheezing during the previous year and 17%
had increased bronchial responsiveness. Olin et al. (7)
found similar levels of FENO in 137 skin prick positive
and 33 skin prick negative healthy adults. Their study
population was not a random sample of healthy adults
because all subjects had occupational low-level irritant
exposure as bleachery workers.
More recently, Olin et al. (11) found atopy being a
signiﬁcant predictor of FENO in the large general
population even after exclusion of subjects with
asthma or current asthma symptoms during the pre-
vious month. However, subjects with earlier history of
chronic or recurrent respiratory symptoms were not
excluded from the analyses, which may affect the
results.In their study,atopy was assessed by measuring
total serum IgE, which has signiﬁcant variation by
gender, age and smoking, as well as considerable over-
lapping of normal and atopic ranges (23).
We found no signiﬁcant correlation between FENO
andthedegreeof atopydeﬁnedeitherasthenumberof
positive reactions or as the total sum of wheal diam-
eters among healthy nonsmoking subjects. This is not
necessarily controversial with the studies by Ho et al.
(24), or by Franklin et al. (8), where signiﬁcant corre-
lation appeared between FENO and the number of
positive skin prick tests, because both studies included
subjects with physician-diagnosed asthma or even
recent respiratory symptoms suggesting asthma.In the
present study, a positive correlation between FENO
andthedegreeof atopydidappearamongtheexcluded
subjects, i.e. subjects with a history or with symptoms
or signs of airway disorder. Excluded subjects were
sensitized to equal numbers of allergens as the healthy
subjects, but their sensitization was more intensive,
and the type of sensitization differed from that in
healthy subjects.
Patients with asthma-like symptoms may have
increased FENO (2),and subclinical inﬂammation can
be present in patients with asthma in remission,result-
ing in elevated FENO (25). Although subjects with
positive skin prick tests are about three times more
likely to develop asthma (26), atopic constitution
deﬁned as positive reactions in skin prick tests or as
elevated allergen-speciﬁc IgE levels in serum, does not
imply presence of a disease or active inﬂammation.Up
to 39% of skin prick positive subjects from a general
adolescent population have been reported to be
asymptomatic (27).
Prieto et al. found increasing FENO levels when
patients with allergic rhinitis were studied during the
pollen season (28), i.e. the mucosal inﬂammation was
activated. In our study, FENO was measured through-
out the year, and no signiﬁcant difference occurred
between FENO levels measured during or out of the
pollenseason.However,theonlyeightFENOmeasure-
ments were performed on atopic subjects during the
pollen season compared with 24 measurements per-
formed out of the pollen season, thus not allowing
conclusive comparison.
Our study population of nonsmoking healthy
asymptomatic adults selected from a random popula-
tion is most relevant for assessment of inﬂuence of
atopic constitution on FENO. Possible airway pathol-
ogy even in asymptomatic subjects was taken into
account by excluding subjects with abnormal spirom-
etry or bronchial challenge. Atopy was assessed objec-
tively according to published guidelines (18), based
on skin prick tests for a large number of common
aeroallergens. To our knowledge, this is the largest
study of such a random healthy population comparing
FENO between skin prick positive and negative sub-
jects. The 27- to 61-year age group represents well the
target adult population for FENO measurements in a
clinical setting. Because smoking is known to reduce
the level of FENO, current smokers were not included
Asymptomatic atopy and exhaled nitric oxide Rouhos et al.
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within weeks after smoking cessation (29), smoking
can cause more chronic detrimental effects on the
airway mucosa, which might inﬂuence FENO produc-
tion. Thus, in addition to nonsmokers, we included
only ex-smokers with very short smoking histories and
several years since smoking cessation.
Reference values based on gender and atopic status
were suggested by the recent study by Travers et al.
(13). Their study excluded subjects with respiratory
symptoms within 12 months or physician-diagnosed
asthma and symptoms or inhaler use within 12
months,aswellasthosewithreversibleairwayobstruc-
tion in lung function. These criteria, however, do not
exclude subjects with mild intermittent asthma, who
often may go undiagnosed and are reported to have
elevated FENO as a sign of ongoing eosinophilic
inﬂammation in the airways (30). The deﬁnition of
atopy was based on skin prick tests performed with
nine common allergens,but the procedure,the criteria
for positive result and the solutions used, were not
described (13). Previously, large differences in the
prevalence of positive reactions have been observed
with different commercial preparations of the same
allergen (31). A very recent study by Olin et al. (12)
suggested reference values of FENO for adults to be
adjusted according to height and age, whereas atopic
status, deﬁned as increased levels of serum IgE, was
found to be of minor importance, thus suggesting
same upper normal limits for both atopic and non-
atopic healthy nonsmoking subjects. Our study found
a signiﬁcant correlation between FENO and height,
but not with FENO and age. The upper 95% limit of
FENO, 29–31 ppb, reported in the present study is in
line with that of 24–53 ppb suggested in the study by
Olin et al. (12) as well as with that of 33 ppb suggested
by Taylor et al. based on earlier data (1).
Our ﬁndings indicate that in healthy asymptomatic
nonsmoking adults, atopic constitution (positive skin
prick test results) per se does not inﬂuence FENO. We
conclude further that elevated FENO is not an indica-
tor of atopic constitution,but indicates NO-producing
inﬂammation in the airways. These ﬁndings suggest
that same reference range can be applied to both skin
prick positive and negative subjects.
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